杰华生物

更新时间：2024-09-14 直链：www.genovabiotech.org.cn

杰华生物

更新时间：2023-11-28 直链：www.genova.cn

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.

更新时间：2023-11-28 直链：westvacpharma.com

公司成于2017年5月，是一家创新生物技术药物研发企业，专注从事免疫治疗抗体药物的设计、研发、验证和临床转化研究。凭借研发团队在肿瘤免疫和重组抗体领域的专业水平和成熟的技术平台，在肿瘤免疫激动性抗体研发方面快速突破；目前公司多个抗体产品进展顺利，包括CD137激动抗体、新型CTLA-4抗体、OX-40抗体等项目，已实现技术转让收入数千万元，总里程碑款近亿元。

更新时间：2023-11-28 直链：www.immunoah.cn

生物医药展会生物制药大会生物技术展览会疫苗大会抗体大会基因年会基因组大会细胞工程大会生物工程大会分子生物学大会细胞生物学大会生物化学大会生物分析大会生物学大会生物制药工程大会生物科技大会生命科学大会生物产业大会生物技术展会生物制药年会生物制药展会BiomaterialsConferenceBiomedicalMaterialsConferenceCardiacInterventionConferenceBiomaterialsAnnualMeetingOrthopedicMaterialsConferenceCardiovascularMaterialsConferenceOralMaterialsConferenceRegenerativeMaterialsConferenceImplantMaterialsConferenceImplantedMedicalDevicesConferenceMedicalMaterialsConference生物材料大会生物医用材料大会心脏介入大会生物材料年会骨科材料大会心血管材料大会口腔材料大会再生医学材料大会植入物材料大会植入医疗器械大会医用材料大会细胞治疗大会分子生物学大会细胞生物学大会细胞治疗论坛细胞大会细胞学年会干细胞年会干细胞研究大会再生医学大会基因大会生物化学大会化学生物学大会生物学大会生命科学大会细胞治疗和免疫治疗，干细胞，组织工程和细胞工程，生物材料和组织相互作用，再生模型，再生分子机制，再生诊断和成像，再生医学基础研究、再生医学临床应用

更新时间：2023-11-28 直链：www.gmexpo.net